Paul Hampel(@hampel_p) 's Twitter Profileg
Paul Hampel

@hampel_p

Hematologist @MayoClinic specializing in CLL and Lymphoma. Tweets are my own.

ID:1134314810315640832

calendar_today31-05-2019 04:25:00

138 Tweets

518 Followers

384 Following

Follow People
Paul Hampel(@hampel_p) 's Twitter Profile Photo

Great work leading this large effort Adam! Novel treatment strategies needed for patients with RT and any prior CLL therapy.

account_circle
Mazie Tsang, MD, MAS, MS(@MazieTsangMD) 's Twitter Profile Photo

Interested in CLL? Consider a job at Mayo Clinic Comprehensive Cancer Center!

The CLL group is phenomenal and has a great spirit of camaraderie and kindness!

If you’re interested in CLL, research, and thrive in a supportive and fun work environment, consider applying!

Interested in CLL? Consider a job at @MayoCancerCare! The CLL group is phenomenal and has a great spirit of camaraderie and kindness! If you’re interested in CLL, research, and thrive in a supportive and fun work environment, consider applying!
account_circle
Othman Al-Sawaf(@Othman_Al_Sawaf) 's Twitter Profile Photo

Check out our latest work on transcriptomic profiles of , drivers of MRD response and 5-year results from CLL14 – all out today in one paper Nature Communications :

nature.com/articles/s4146…

Key results in a brief 🧵

account_circle
iwCLL(@iwCLL) 's Twitter Profile Photo

— Now accepting abstract submissions!

Review abstract submission guidelines & submit here: loom.ly/Y9MaYKw

The submission deadline is May 31, 2023 at 11:59 pm EST.

Learn more at IWCLL2023.ORG.

#iwCLL2023 — Now accepting abstract submissions! Review abstract submission guidelines & submit here: loom.ly/Y9MaYKw The submission deadline is May 31, 2023 at 11:59 pm EST. Learn more at IWCLL2023.ORG.
account_circle
Yucai Wang, MD, PhD(@YucaiWangMD) 's Twitter Profile Photo

MIRACLE, an investigator-initiated study of MRD-guided, time-limited frontline therapy with pirtobrutinib and venetoclax for CLL/SLL, sponsored by Loxo@Lilly Oncology Medical, is now open Mayo Clinic Comprehensive Cancer Center.
clinicaltrials.gov/ct2/show/NCT05…

MIRACLE, an investigator-initiated study of MRD-guided, time-limited frontline therapy with pirtobrutinib and venetoclax for CLL/SLL, sponsored by @LoxoLillyOnc, is now open @MayoCancerCare. clinicaltrials.gov/ct2/show/NCT05…
account_circle
Amber Koehler, PA-C(@hemepa_c) 's Twitter Profile Photo

Check out the latest publication in Blood Reviews: CLL update 2022: A continuing evolution in care Sameer Parikh Paul Hampel neil kay

pubmed.ncbi.nlm.nih.gov/35151528/

account_circle